IBD Treatment: Thiopurines Remain Vital Despite Rise of Biologics, But Mild Infection Risk Needs Attention
For individuals battling inflammatory bowel disease (IBD), the treatment landscape is constantly evolving. While newer biologic and compact molecule therapies offer promising results, their high cost and limited accessibility mean older, more established treatments like thiopurines – azathioprine and mercaptopurine – continue to play a crucial role in managing the condition. Recent research underscores this point, while also highlighting a need for careful monitoring of infection risk.
The Ongoing Relevance of Thiopurines
IBD, encompassing conditions like Crohn’s disease and ulcerative colitis, is no longer confined to Western nations. Its increasing global prevalence demands accessible and affordable treatment options. Biologics, while effective, remain out of reach for many, particularly in developing countries. This reality keeps thiopurines a cornerstone of IBD management, offering a viable alternative where newer therapies are unavailable or financially prohibitive.
New Study Reveals Mild Infection Risk with Thiopurines
A retrospective study published in the Journal of Clinical Gastroenterology examined the infection risk associated with thiopurine initiation in 244 IBD patients. Researchers found that overall infection rates increased after starting thiopurines, rising from 22.4 to 31.8 per 100 person-years. However, the increase was largely driven by mild infections, particularly viral infections and upper respiratory tract infections. Importantly, there was no significant increase in moderate-to-severe infections, bacterial infections, or gastrointestinal tract infections.
The study revealed a shift in infection types. Before thiopurine treatment, bacterial infections were most common (57.8%). Afterward, viral infections became more prevalent (55.3%), while gastrointestinal infections decreased.
Did you know? Having an existing infection before starting thiopurine therapy increased the risk of infection after initiation.
Understanding the Infection Profile
The findings suggest that while thiopurines may slightly increase susceptibility to common, less severe infections, they don’t necessarily heighten the risk of serious complications. Researchers emphasize that the cumulative effect of these mild infections – impacting daily functioning and overall well-being – should not be overlooked. The increased incidence of viral infections (IRR, 2.3) and upper respiratory tract infections (IRR, 2.4) were particularly notable.
Future Trends: Optimizing Thiopurine Therapy and Personalized Medicine
The continued use of thiopurines necessitates a focus on optimizing their application. Pharmacogenomic testing, analyzing genes involved in drug metabolism, is gaining traction. Variations in the TPMT gene, for example, can predict an individual’s risk of myelotoxicity (bone marrow suppression), a serious side effect. Similarly, research suggests that variations in the NUDT15 gene may be more relevant for predicting toxicity in Asian populations.
Age is also a critical factor. Elderly patients are generally at higher risk of complications from thiopurine therapy, requiring careful consideration of dosage and monitoring.
Pro Tip: Regular blood tests are essential for monitoring thiopurine levels and identifying potential side effects. Discuss any concerns with your gastroenterologist.
The Role of Monitoring and Proactive Management
Given the increased risk of mild infections, proactive management is key. This includes:
- Vaccinations: Ensuring patients are up-to-date on recommended vaccinations, particularly against influenza and pneumococcal disease.
- Hygiene Practices: Reinforcing quality hygiene practices, such as frequent handwashing.
- Early Intervention: Promptly addressing any signs of infection, even if mild.
FAQ
Q: Are thiopurines still a good option for IBD treatment?
A: Yes, especially when biologics are inaccessible or unaffordable. They remain a valuable treatment option for maintaining remission.
Q: What are the most common side effects of thiopurines?
A: Increased risk of mild infections, particularly viral infections, and potential for myelotoxicity. Regular monitoring can help manage these risks.
Q: What is pharmacogenomic testing?
A: It’s a test that analyzes your genes to predict how you might respond to certain medications, like thiopurines, and identify potential risks.
Q: Should I be concerned about getting sick more often if I start thiopurines?
A: You may experience a slight increase in mild infections, like colds. However, the risk of serious infections doesn’t appear to be significantly increased.
The findings from this study reinforce the idea that thiopurine monotherapy remains a relatively safe treatment option for maintaining remission in IBD, particularly in settings where access to biologics and small molecules is limited.
Want to learn more about IBD and treatment options? Explore resources from NPS MedicineWise.
